argenx (ARGX) stock
Follow ARGX's trial news. Pro members can get an alert when argenx files news, and see its trials, share raises, and its CEO's filings.
What's next for ARGX
From argenx’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Dilution on the horizon
No shelf registration of its own or at-the-market program on file in the last three years.
Insiders
No open-market buys or sales by its officers or directors in their filings of the last year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 28 daysINOInovio Pharmaceuticals
INOINO-3107
- In 39 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 51 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why ARGX scores 5
Below AverageTransition, 1 of 14 checks firingWhat the Quality Score means
- +1Chart checks 1 of 14 firing right now, one point each
- +2Long-term trend above a rising 200-day average
- Size adds
- Persistence adds
What's next
Reports Thu Oct 22, before the open
What would turn ARGX's score around: 4 things, for Pro members
Here is what Pro members see.
Every stock has a live page like this, ARGX included: the price in real time, the full chart, all 14 checks, and every line of its score.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
ARGX has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1435.8
- MACD (12, 26, 9)Below signal
- 50-day average$956.72
- 200-day average$851.23
- ADX 1418.2
- Support$886.25
- Resistance$933.99
- Volume1.3x
How ARGX ranks in Biotech
ARGX is #73 of 300 by Quality Score. The top three are shown with their scores, and more by name.
KNSA7/1418
EXEL7/1417
AMRX6/1417
ANIXOpen for its score
AQSTOpen for its score
ARQTOpen for its score
ARTVOpen for its score
ARGX1/145
When does ARGX report earnings, and what happens after?
Reports Thu Oct 22, before the open (in 20 days). The company has set the date.
About argenx
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of ARGX's score, with the points and the reason
- All 14 checks on ARGX and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on ARGX
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.